DNLI News and Press, Denali Therapeutics Inc. From 04/17/23

2023-04-17 06:52:08 ET Summary Denali Therapeutics is poised to revolutionize the industry with its proprietary Transport Vehicle (TV) technology, designed to effectively cross the blood-brain barrier. The company's robust and diversified therapeutic portfolio includes seven progr...

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV):Amyloid beta program (AT...

Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers associated with the integrated stress response (ISR) Clinical pharmacokinetic and ISR pharmacodynamic data, along with preclinical data, are consistent with extensive CNS distribution a...

Denali Therapeutics press release ( NASDAQ: DNLI ): Q4 GAAP EPS of -$0.75 beats by $0.03 . Revenue of $10.28M (-17.8% Y/Y) misses by $1.01M . For further details see: Denali Therapeutics GAAP EPS of -$0.75 beats by $0.03, revenue of $10.28M misses by $1.01M

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal st...

Over 49 weeks of DNL310 (ETV:IDS) treatment in the Phase 1/2 study, positive changes across measures of exploratory clinical outcomes including VABS-II (adaptive behavior) and BSID-III (cognitive capabilities) scores and global impression scales were observed Interim Phase 1/2 data also s...

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases and lysosomal storage ...

Summary FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns. If the deal closes, the stock should rise 30%; if it fails, FSTX still has very valuable assets. The only r...

Denali Therapeutics ( NASDAQ: DNLI ) said it will receive a a milestone payment of $25M as Sanofi ( NASDAQ: SNY ) began dosing in a phase 2 trial of SAR443820 (DNL788) to treat patients with multiple sclerosis. SAR443820 is a central nervous system (CNS) penetra...

Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosis Denali to receive a milestone payment of $25 million from Sanofi for Phase 2 clinical trial initiation Development of RIPK1 inhibitor program continues in a broad...